KCA
Search
- Page Path
- HOME > Search
Case Reports
- Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma
- Hye Sook Kim, Soon Wook Lee, Yoon Ji Choi, Sang Won Shin, Yeul Hong Kim, Min Sun Cho, Soon Nam Lee, Kyong Hwa Park
- Cancer Res Treat. 2015;47(3):534-538. Published online October 17, 2014
- DOI: https://doi.org/10.4143/crt.2013.151
-
Abstract
PDF
PubReader
ePub - We report a case of a 56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-cell lymphoma with a BRCA1 gene mutation. Evidence is mounting that there is a large increase in the risk for hematologic malignancies among patients with genetic changes in the BRCA pathways. The genomic analysis demonstrated a frameshift mutation in the BRCA1 gene: 277_279delinsCC (Phe93fs). It is a novel BRCA1 mutation that has never been reported, and caused malignant lymphoma as well as breast and ovarian cancer.
-
Citations
Citations to this article as recorded by
- An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi
BMC Cancer.2020;[Epub] CrossRef - Lymphoma in Australian Border Collies: survey results and pedigree analyses
KY Cheng, PXY Soh, PF Bennett, P Williamson
Australian Veterinary Journal.2019; 97(1-2): 14. CrossRef - Germline mutations predisposing to diffuse large B-cell lymphoma
O C Leeksma, N F de Miranda, H Veelken
Blood Cancer Journal.2017; 7(2): e532. CrossRef - Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation
Petra Škerl, Mateja Krajc, Ana Blatnik, Srdjan Novaković
Oncology Reports.2017; 38(1): 279. CrossRef - Risk of lymphoma subtypes by occupational exposure in Southern Italy
Giovanni Maria Ferri, Giorgina Specchia, Patrizio Mazza, Giuseppe Ingravallo, Graziana Intranuovo, Chiara Monica Guastadisegno, Maria Luisa Congedo, Gianfranco Lagioia, Maria Cristina Loparco, Annamaria Giordano, Tommasina Perrone, Francesco Guadio, Cater
Journal of Occupational Medicine and Toxicology.2017;[Epub] CrossRef - How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy
Bin Zhang, Xia Zhang, Minghuan Li, Li Kong, Xiaoqin Deng, Jinming Yu
Cancer Biology & Therapy.2016; 17(2): 125. CrossRef - Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients Finding Founder Mutations
Min Chul Choi, Jin-Hyung Heo, Ja-Hyun Jang, Sang Geun Jung, Hyun Park, Won Duk Joo, Chan Lee, Je Ho Lee, Jun Mo Lee, Yoon Young Hwang, Seung Jo Kim
International Journal of Gynecological Cancer.2015; 25(8): 1386. CrossRef
- An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
- 13,717 View
- 121 Download
- 6 Web of Science
- 7 Crossref
- Cancer of Unknown Primary Finally Revealed to Be a Metastatic Prostate Cancer: A Case Report
- Jung Yeon Cho, Eun Jin Shim, In Seon Kim, Eun Mi Nam, Moon Young Choi, Kyung Eun Lee, Yeung Chul Mun, Chu Myoung Seoung, Soon Nam Lee, Dong Eun Song, Woon Sup Han
- Cancer Res Treat. 2009;41(1):45-49. Published online March 31, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.1.45
-
Abstract
PDFPubReaderePub
The vast majority of patients with metastatic prostate cancer present with bone metastases and high prostate specific antigen (PSA) level. Rarely, prostate cancer can develop in patients with normal PSA level. Here, we report a patient who presented with a periureteral tumor of unknown primary site that was confirmed as prostate adenocarcinoma after three years with using specific immunohistochemical examination. A 64-year old man was admitted to our hospital with left flank pain associated with masses on the left pelvic cavity with left hydronephrosis. All tumor markers including CEA, CA19-9, and PSA were within the normal range. After an exploratory mass excision and left nephrectomy, the pelvic mass was diagnosed as poorly differentiated carcinoma without specific positive immunohistochemical markers. At that time, we treated him as having a cancer of unknown primary site. After approximately three years later, he revisited the hospital with a complaint of right shoulder pain. A right scapular mass was newly detected with a high serum PSA level (101.7 ng/ml). Tissues from the scapular mass and prostate revealed prostate cancer with positive immunoreactivity for P504S, a new prostate cancer-specific gene. The histological findings were the same as the previous pelvic mass; however, positive staining for PSA was observed only in the prostate mass. This case demonstrates a patient with prostate cancer and negative serological test and tissue staining that turned out to be positive during progression. We suggest the usefulness of newly developed immunohistochemical markers such as P504S to determine the specific primary site of metastatic poorly differentiated adenocarcinoma in men.
-
Citations
Citations to this article as recorded by- A Unique Case of Prostate Carcinoma Presenting as Retroperitoneal Lymphadenopathy With Normal Levels of Prostate-Specific Antigen and a Prostate of Normal Size: A Case Report
Swapnil Patil, Mayank Mundada, Pradnya M Diggikar, Raju Hansini Reddy, Sree Vidya Yekkaluru
Cureus.2024;[Epub] CrossRef - Prostate cancer metastasis to the distal phalanx of the left hallux: The first confirmed case and literature review
Xinbing Sui, Yan Hu, Cheng Zhang, Hongming Pan, Da Li
Oncology Letters.2016; 12(2): 1074. CrossRef - Metastasis of prostate carcinoma in the mandible manifesting as numb chin syndrome
Secil Aksoy, Kaan Orhan, Sebnem Kursun, Mehmet Eray Kolsuz, Berkan Celikten
World Journal of Surgical Oncology.2014;[Epub] CrossRef
- A Unique Case of Prostate Carcinoma Presenting as Retroperitoneal Lymphadenopathy With Normal Levels of Prostate-Specific Antigen and a Prostate of Normal Size: A Case Report
- 9,745 View
- 56 Download
- 3 Crossref
Original Articles
- Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
- Kyung Hee Lee, Myung Soo Hyun, Hoon-Kyo Kim, Hyung Min Jin, Jinmo Yang, Hong Suk Song, Young Rok Do, Hun Mo Ryoo, Joo Seop Chung, Dae Young Zang, Ho-Yeong Lim, Jong Youl Jin, Chang Yeol Yim, Hee Sook Park, Jun Suk Kim, Chang Hak Sohn, Soon Nam Lee
- Cancer Res Treat. 2009;41(1):12-18. Published online March 31, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.1.12
-
Abstract
PDFPubReaderePub
Purpose Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer.
Materials and Methods One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks.
Results At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths.
Conclusion Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.
-
Citations
Citations to this article as recorded by- The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu
Cancer Research and Treatment.2025; 57(1): 39. CrossRef - Quantum mechanical approaches and molecular docking analysis of platinum metal-based anticancer drugs Lobaplatin and Heptaplatin targeting cancer DNA - a comparative analysis
Madhavi Sahadevan, Mullainathan Sundaram, Karunagaran Subramanian
Chemical Physics Letters.2024; 842: 141191. CrossRef - Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
S. Shruthi, K. Bhasker Shenoy
ChemistrySelect.2024;[Epub] CrossRef - Recent Advances on Pt-Based Compounds for Theranostic Applications
Giulia Ferrari, Ines Lopez-Martinez, Thomas Wanek, Claudia Kuntner, Diego Montagner
Molecules.2024; 29(15): 3453. CrossRef - Hallmarks of anticancer and antimicrobial activities of corroles
Vinay K. Sharma, Yehuda G. Assaraf, Zeev Gross
Drug Resistance Updates.2023; : 100931. CrossRef - Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef - Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity
Galdina V. Suárez-Moreno, Delia Hernández-Romero, Óscar García-Barradas, Óscar Vázquez-Vera, Sharon Rosete-Luna, Carlos A. Cruz-Cruz, Aracely López-Monteon, Jesús Carrillo-Ahumada, David Morales-Morales, Raúl Colorado-Peralta
Coordination Chemistry Reviews.2022; 472: 214790. CrossRef - Metalofármacos en la terapia contra el cáncer
Elizabeth Márquez López, Esmeralda Sánchez Pavón, Rodolfo Peña Rodríguez, Delia Hernández Romero, José M. Rivera Villanueva, Raúl Colorado Peralta, David Morales Morales
TECNOCIENCIA Chihuahua.2022; 16(3): e1010. CrossRef - Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Dan Gibson
Journal of Inorganic Biochemistry.2021; 217: 111353. CrossRef - Monofunctional Platinum(II) Anticancer Agents
Suxing Jin, Yan Guo, Zijian Guo, Xiaoyong Wang
Pharmaceuticals.2021; 14(2): 133. CrossRef - Pt(IV) Prodrugs with NSAIDs as Axial Ligands
Daniil Spector, Olga Krasnovskaya, Kirill Pavlov, Alexander Erofeev, Peter Gorelkin, Elena Beloglazkina, Alexander Majouga
International Journal of Molecular Sciences.2021; 22(8): 3817. CrossRef - Multi-action Pt(IV) anticancer agents; do we understand how they work?
Dan Gibson
Journal of Inorganic Biochemistry.2019; 191: 77. CrossRef - TOXview: a novel graphical presentation of cancer treatment toxicity profiles
Lok Lam Ngai, Emil ter Veer, Héctor G. van den Boorn, E. Hugo van Herk, Jessy Joy van Kleef, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Acta Oncologica.2019; 58(8): 1138. CrossRef - Photoactivated platinum-based anticancer drugs
Muhammad Imran, Wagma Ayub, Ian S. Butler, Zia-ur-Rehman
Coordination Chemistry Reviews.2018; 376: 405. CrossRef - Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi, Atsuo Takashima, Kentaro Sakamaki, Satoshi Morita, Narikazu Boku
Cancer Chemotherapy and Pharmacology.2018; 81(6): 981. CrossRef - An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer
Dimitris Bertsimas, Allison O’Hair, Stephen Relyea, John Silberholz
Management Science.2016; 62(5): 1511. CrossRef - Platinum(iv) anticancer prodrugs – hypotheses and facts
Dan Gibson
Dalton Transactions.2016; 45(33): 12983. CrossRef - Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines
Pavel Štarha, Zdeněk Trávníček, Lucia Pazderová, Zdeněk Dvořák
Journal of Inorganic Biochemistry.2016; 162: 109. CrossRef - VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells
Sergey A. Shein, Ilya I. Kuznetsov, Tatiana O. Abakumova, Pavel S. Chelushkin, Pavel A. Melnikov, Anna A. Korchagina, Dmitry A. Bychkov, Irina F. Seregina, Mikhail A. Bolshov, Alexander V. Kabanov, Vladimir P. Chekhonin, Natalia V. Nukolova
Molecular Pharmaceutics.2016; 13(11): 3712. CrossRef - Condensations of single DNA molecules induced by heptaplatin and its chiral isomer
Hong-Yan Zhang, Yu-Ru Liu, Wei Li, Hui Li, Shuo-Xing Dou, Ping Xie, Wei-Chi Wang, Peng-Ye Wang
AIP Advances.2014;[Epub] CrossRef - Nanocarriers for delivery of platinum anticancer drugs
Hardeep S. Oberoi, Natalia V. Nukolova, Alexander V. Kabanov, Tatiana K. Bronich
Advanced Drug Delivery Reviews.2013; 65(13-14): 1667. CrossRef - Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo
Investigational New Drugs.2012; 30(3): 1224. CrossRef - Cellular interactions of platinum drugs
Ezequiel Wexselblatt, Eylon Yavin, Dan Gibson
Inorganica Chimica Acta.2012; 393: 75. CrossRef - What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt, Dan Gibson
Journal of Inorganic Biochemistry.2012; 117: 220. CrossRef - Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma
X.-L. Zhang, H.-J. Shi, S.-Z. Cui, Y.-Q. Tang, M.-C. Ba
European Journal of Surgical Oncology (EJSO).2011; 37(6): 466. CrossRef - The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef
- The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
- 12,203 View
- 114 Download
- 26 Crossref
- Discrepant Views of Korean Medical Oncologists and Cancer Patients on Complementary and Alternative Medicine
- Do Yeun Kim, Bong-Seog Kim, Kyung Hee Lee, Myung Ah Lee, Young Seon Hong, Sang Won Shin, Soon Nam Lee
- Cancer Res Treat. 2008;40(2):87-92. Published online June 30, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.2.87
-
Abstract
PDFPubReaderePub
Purpose This study was designed to evaluate the communication gap between Korean medical oncologists and cancer patients on complementary and alternative medicine (CAM).
Materials and Methods Cross sectional studies utilized the responses of 59 medical oncologists and 211 patients. To understand the communication gap, perceived reasons and nondisclosure of CAM use, reactions of physicians to disclosure, and expectations for CAM were analyzed. Data were compared with use of the chi-squared test.
Results Both medical oncologists and patients were in accord that CAM use would privde the patients with a feeling of hope. The medical oncologists believed more often than patients to attribute CAM use for control over medical care decisions, for the treatment of an incurable disease or as a nontoxic approach (p<0.05). Regarding reasons for nondisclosure, medical oncologists were more likely to think that physicians would not understand the use of CAM, discontinue treatment or disapprove of the use of CAM (p<0.0001). Patients attributed nondisclosure mainly to the lack of questioning about CAM. Medical oncologists were more likely to warn of the risks with CAM use and less likely to encourage the use of CAM than perceived by patients (p=0.01). Patients expected that CAM could cure disease, extend survival, relieve symptoms and improve the immune system or quality of life more often than medical oncologists (p<0.05).
Conclusion Given the discrepant views of medical oncologists and patients on the use of CAM, medical oncologists should be aware of the discrepancies and attempt to resolve any differences.
-
Citations
Citations to this article as recorded by- Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial
Wan-Qin Chong, Maria Jannet Mogro, Asrie Arsad, Bee-Choo Tai, Soo-Chin Lee
Supportive Care in Cancer.2021; 29(7): 3689. CrossRef - Discrepant Views of Oncologists and Cancer Patients on Complementary and Alternative Medicine in a Chinese General Hospital
Geliang Yang, Huiqing Zhang, Zheng Gan, Yifu Fan, Wei Gu, Changquan Ling
Integrative Cancer Therapies.2018; 17(2): 451. CrossRef - Information and Training Needs Regarding Complementary and Alternative Medicine: A Cross-sectional Study of Cancer Care Providers in Germany
Gudrun E. Klein, Corina Guethlin
Integrative Cancer Therapies.2018; 17(2): 380. CrossRef - China’s cancer patients’ perceptions, attitudes and participation in clinical trials of complementary and alternative medicine: A multi-center cross-sectional study
Yifu Fan, Huiqing Zhang, Geliang Yang, Cheng Wu, Yuyu Guo, Changquan Ling
European Journal of Integrative Medicine.2018; 19: 115. CrossRef - National survey of China's oncologists' knowledge, attitudes, and clinical practice patterns on complementary and alternative medicine
Geliang Yang, Richard Lee, Huiqing Zhang, Wei Gu, Peiying Yang, Changquan Ling
Oncotarget.2017; 8(8): 13440. CrossRef - Expected and perceived efficacy of complementary and alternative medicine: A comparison views of patients with cancer and oncologists
Sang Hyuck Kim, Dong Wook Shin, You-Seon Nam, So Young Kim, Hyung-kook Yang, Be Long Cho, Keeho Park, Heui-Sug Jo, Chang-Yeol Yim, Sin Kam, Jong-Hyock Park
Complementary Therapies in Medicine.2016; 28: 29. CrossRef - Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers
Gyeongyeon Hong, Jennifer White, Lihong Zhong, Linda E. Carlson
Integrative Cancer Therapies.2015; 14(4): 305. CrossRef - National Survey of US Oncologists' Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by Patients With Cancer
Richard T. Lee, Andrea Barbo, Gabriel Lopez, Amal Melhem-Bertrandt, Heather Lin, Olufunmilayo I. Olopade, Farr A. Curlin
Journal of Clinical Oncology.2014; 32(36): 4095. CrossRef - Perception and attitude of Jordanian physicians towards complementary and alternative medicine (CAM) use in oncology
Amal Al-Omari, Mohammad Al-Qudimat, Amid Abu Hmaidan, Luna Zaru
Complementary Therapies in Clinical Practice.2013; 19(2): 70. CrossRef - Investigation into the Use of Complementary and Alternative Medicine and Factors Affecting Use in Korean Patients with Brain Tumors
Yong Soon Shin, Jeong A Lee, So Hyun Bae, Su Youn Lee, Min Kyeong Jang
Journal of Korean Academy of Fundamentals of Nursing.2013; 20(2): 147. CrossRef - Complementary and alternative medicine use and assessment of quality of life in Korean breast cancer patients: a descriptive study
Eunyoung Kang, Eun Joo Yang, Sun-Mi Kim, Il Yong Chung, Sang Ah Han, Do-Hoon Ku, Soek-Jin Nam, Jung-Hyun Yang, Sung-Won Kim
Supportive Care in Cancer.2012; 20(3): 461. CrossRef - Validation of the Korean Integrative Medicine Attitude Questionnaire (IMAQ)
Jung-Ha Kim, Jung-Bok Lee, Duk-Chul Lee
Korean Journal of Family Medicine.2011; 32(3): 197. CrossRef
- Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial
- 9,556 View
- 54 Download
- 12 Crossref
- An Evaluation of Nutrition Support for Terminal Cancer Patients at Teaching Hospitals in Korea
- Do Yeun Kim, Sang Min Lee, Kyoung Eun Lee, Hye Ran Lee, Jee Hyun Kim, Keun-Wook Lee, Jong Seok Lee, Soon Nam Lee
- Cancer Res Treat. 2006;38(4):214-217. Published online December 31, 2006
- DOI: https://doi.org/10.4143/crt.2006.38.4.214
-
Abstract
PDFPubReaderePub
Purpose We wanted to analyze the use of nutrition support for terminal cancer patients, the effect of discussing withdrawal of nutrition support and do-not-resuscitate (DNR) consent on the use of intravenous nutrition during the patient's last week of life and at the time of death.
Materials and Methods The study involved 362 patients with terminal cancer from four teaching hospitals, and they all died between January 1 2003 and December 31 2005. The basic demographic data, the use of intravenous nutrition during the patient's last week of life and at death, discussion of terminal nutrition withdrawal and DNR consent were evaluated.
Results In the week before death, the patients received artificial nutrition such as total parenteral nutrition (31%), intravenous albumin infusion (25%), and feeding tube placements (9%). A discussion concerning withdrawal of nutrition support was limited to 25 (7%) patients. DNR consent was obtained from 294 (81%) patients. None of the patients were directly involved in any of these decisions. The discussion about withdrawal of terminal nutrition and DNR consent with the patient's surrogates did not have any effect on reducing the use of parenteral nutrition.
Conclusion The majority of patients dying of terminal cancer were still given potentially futile nutritional support. Modern clinical guidelines and ethical education about nutritional support at the end of life care is urgently needed in Korean medical practice to provide proper administration of terminal nutrition for end of life care.
-
Citations
Citations to this article as recorded by- Report of the Lancet Commission on the Value of Death: bringing death back into life
Libby Sallnow, Richard Smith, Sam H Ahmedzai, Afsan Bhadelia, Charlotte Chamberlain, Yali Cong, Brett Doble, Luckson Dullie, Robin Durie, Eric A Finkelstein, Sam Guglani, Melanie Hodson, Bettina S Husebø, Allan Kellehear, Celia Kitzinger, Felicia Marie Kn
The Lancet.2022; 399(10327): 837. CrossRef - A National Study of Life-Sustaining Treatments in South Korea: What Factors Affect Decision-Making?
So-Youn Park, Bomyee Lee, Jeong Yeon Seon, In-Hwan Oh
Cancer Research and Treatment.2021; 53(2): 593. CrossRef - The Trend of Aggressive Treatments in End-of-Life Care for Older People With Dementia After a Policy Change in Taiwan
Ying Hsin Hsu, Ming Yueh Chou, Hsiu-Min Chen, Wei-Cheng Chang, Che Sheng Chu, Yu-Chun Wang, Chiao-Lin Hsu, Chih-Kuang Liang, Ching-Chih Lee, Yu Te Lin
Journal of the American Medical Directors Association.2020; 21(6): 858. CrossRef - Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
Cancer Research and Treatment.2020; 52(3): 917. CrossRef - Nutrition Intervention through Interdisciplinary Medical Treatment in Hospice Patients: From Admission to Death
Hyelim Kang, Yu Jin Yang, Juyeon Park, Gyu Jin Heo, Jeong-Im Hong, Hye-Jin Kim
Clinical Nutrition Research.2018; 7(2): 146. CrossRef - Evidence for overuse of medical services around the world
Shannon Brownlee, Kalipso Chalkidou, Jenny Doust, Adam G Elshaug, Paul Glasziou, Iona Heath, Somil Nagpal, Vikas Saini, Divya Srivastava, Kelsey Chalmers, Deborah Korenstein
The Lancet.2017; 390(10090): 156. CrossRef - A Randomized Phase II Study To Assess the Effectiveness of Fluid Therapy or Intensive Nutritional Support on Survival in Patients with Advanced Cancer Who Cannot be Nourished via Enteral Route
So Yeon Oh, Hyun Jung Jun, Sung Jae Park, In Ki Park, Ga Jin Lim, Yeonsil Yu, Sung-Ja Cho, Aeran Song
Journal of Palliative Medicine.2014; 17(11): 1266. CrossRef - Evaluation of parenteral nutritional support in the surgical and medical wards of a referral teaching hospital
Samaneh Bairami, Sepideh Elyasi, Hossein Khalili, Saeed Reza Jamali-Moghadam
DARU Journal of Pharmaceutical Sciences.2012;[Epub] CrossRef - Awareness and Attitude Change after End-of-Life Care Education for Medical Students
Hyun Kyung Kim, Eunmi Nam, Kyoung Eun Lee, Soon Nam Lee
The Korean Journal of Hospice and Palliative Care.2012; 15(1): 30. CrossRef - Charactersitics and issues of guideline to withdrawal of a life-sustaining therapy
Younsuck Koh, Dae-Seog Heo, Young Ho Yun, Jeong-Lim Moon, Hyoung Wook Park, Ji Tae Choung, Hyo Sung Jung, Bark Jang Byun, Yoon-Seong Lee
Journal of the Korean Medical Association.2011; 54(7): 747. CrossRef - Nasogastric feeding at the end of life: A virtue ethics approach
Lalit Krishna
Nursing Ethics.2011; 18(4): 485. CrossRef - Chinese Familial Tradition and Western Influence: A Case Study in Singapore on Decision Making at the End of Life
Zheng Jie Marc Ho, Lalit Kumar Radha Krishna, Chung Pheng Alethea Yee
Journal of Pain and Symptom Management.2010; 40(6): 932. CrossRef
- Report of the Lancet Commission on the Value of Death: bringing death back into life
- 10,191 View
- 71 Download
- 12 Crossref
Case Report
- Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma
- Hae Sun Jung, Gun-Woo Byun, Kyoung-Eun Lee, Yeung Chul Mun, Seung Hyun Nam, Jung Mi Kwon, Shi Nae Lee, Seock-Ah Im, Chu-Myong Seong, Soon Nam Lee
- Cancer Res Treat. 2005;37(6):370-373. Published online December 31, 2005
- DOI: https://doi.org/10.4143/crt.2005.37.6.370
-
Abstract
PDFPubReaderePub
FA (Fanconi's Anemia) is an autosomal recessive disorder that is characterized by pancytopenia with bone marrow hypoplasia, diverse congenital abnormalities and an increased predisposition towards malignancy. The mainstay of the treatment for these cancers has been surgery, because of the hypersensitive reactions of FA patients to DNA cross- linking agents or radiation. Therefore, there has been no effective therapy for advanced squa mous cell carcinoma. We report here on a patient suffering from advanced multiple squamous cell carcinoma and hepatocellular carcinoma along with an FA, and this patient was treated with gefitinib.
-
Citations
Citations to this article as recorded by- Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review
Siyao Deng, Wenjing Ye, Shichuan Zhang, Guiquan Zhu, Peng Zhang, Yanqiong Song, Fanglei Duan, Jinyi Lang, Shun Lu
Cancer Management and Research.2021; Volume 13: 3145. CrossRef - Treatment of Fanconi Anemia–Associated Head and Neck Cancer: Opportunities to Improve Outcomes
Rex H. Lee, Hyunseok Kang, Sue S. Yom, Agata Smogorzewska, Daniel E. Johnson, Jennifer R. Grandis
Clinical Cancer Research.2021; 27(19): 5168. CrossRef - Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Helena Montanuy, Águeda Martínez-Barriocanal, José Antonio Casado, Llorenç Rovirosa, Maria José Ramírez, Rocío Nieto, Carlos Carrascoso-Rubio, Pau Riera, Alan González, Enrique Lerma, Adriana Lasa, Jordi Carreras-Puigvert, Thomas Helleday, Juan A. Bueren,
Clinical Cancer Research.2020; 26(12): 3044. CrossRef - Angiogenesis in chronic liver disease and its complications
Stephanie Coulon, Femke Heindryckx, Anja Geerts, Christophe Van Steenkiste, Isabelle Colle, Hans Van Vlierberghe
Liver International.2011; 31(2): 146. CrossRef
- Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review
- 9,745 View
- 70 Download
- 4 Crossref
Original Articles
- Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors
- Eunmi Nam, Soon Nam Lee, Seock-Ah Im, Do-Yeun Kim, Kyoung Eun Lee, Sun Hee Sung
- Cancer Res Treat. 2005;37(3):165-170. Published online June 30, 2005
- DOI: https://doi.org/10.4143/crt.2005.37.3.165
-
Abstract
PDFPubReaderePub
Purpose Previous epidemiologic studies have demonstrated that nonsteroidal anti-inflammatory drugs can reduce the risk of breast cancer, and this possibly happens via cyclooxygenase (COX) inhibition. Moreover, growth factor-inducible COX-2, which is overexpressed in neoplastic tissue, is an attractive therapeutic target. Thus, we evaluated the expression of COX-2 in breast cancer tissues, and we assessed the association between COX-2 expression and HER-2/neu expression and also with several clinicopathological features.
Materials and Methods We analyzed the surgical specimens from 112 women with breast cancer who had undergone lumpectomy or mastectomy. The expressions of COX-2, HER-2/neu, MMP-2 and TIMP-2 were determined immunohistochemically. The correlations between COX-2 expression and several variables, including clinicopathological factors, HER-2/neu expression, MMP-2 expression and TIMP-2 expression were analyzed. Survival analysis was also performed with respect to COX-2 overexpression.
Results The overexpression of COX-2 protein was observed in 28.6% of the breast cancer tissues. Tumors with lymph node metastasis more frequently showed COX-2 overexpression than did those tumors without metastasis (p=0.039), and the increased COX-2 expression correlated positively with HER-2/neu overexpression (p=0.000). No significant differences were found for the MMP-2 or TIMP-2 expression rates in the COX-2 positive and negative groups. The survival analysis revealed no significant differences according to the COX-2 expression.
Conclusion This study results suggest that increased COX-2 expression is related with the progression of breast cancer, e.g., with lymph node invasion. COX-2 overexpression found to be related with HER-2/neu overexpression, but not with MMP-2 or TIMP-2 expression. These results support the potential use of selective agents that inhibit COX-2 or HER-2/neu for the management of breast cancer.
-
Citations
Citations to this article as recorded by- Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer
Zhongqi Liu, Shi Cheng, Ganglan Fu, Fengtao Ji, Chengli Wang, Minghui Cao
Life Sciences.2020; 251: 117604. CrossRef - Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer
Joyce L. Moraes, Amanda B. Moraes, Veronica Aran, Marcelo R. Alves, Luciene Schluckbier, Mariana Duarte, Edson Toscano, Mauro Zamboni, Cinthya Sternberg, Emanuela de Moraes, José R. Lapa E Silva, Carlos Gil Ferreira
Molecular and Clinical Oncology.2017; 6(4): 494. CrossRef - Cyclooxygenase-2 Expression in Invasive Breast Carcinomas of No Special Type and Correlation with Pathological Profiles Suggest a Role in Tumorigenesis Rather than Cancer Progression
Nurul Akmar Misron, Lai-Meng Looi, Nik Raihan Nik Mustapha
Asian Pacific Journal of Cancer Prevention.2015; 16(4): 1553. CrossRef - Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients
Justyna Urban, Łukasz Kuźbicki, Grzegorz Szatkowski, Agata Stanek-Widera, Dariusz Lange, Barbara W Chwirot
BMC Cancer.2014;[Epub] CrossRef - Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients
Isabel Sicking, Karlien Rommens, Marco J Battista, Daniel Böhm, Susanne Gebhard, Antje Lebrecht, Cristina Cotarelo, Gerald Hoffmann, Jan G Hengstler, Marcus Schmidt
BMC Cancer.2014;[Epub] CrossRef
- Postoperative administration of ketorolac averts morphine-induced angiogenesis and metastasis in triple-negative breast cancer
- 10,004 View
- 70 Download
- 5 Crossref
- Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study
- Jung Hye Choi, Myung Ju Ahn, Seock Ah Im, Bong Seog Kim, Ho Suk Oh, Heung Woo Lee, Yeung Chul Mun, Chu Myung Seong, Soon Nam Lee, Young Yeul Lee, Il Young Choi, In Soon Kim
- Cancer Res Treat. 2003;35(3):213-217. Published online June 30, 2003
- DOI: https://doi.org/10.4143/crt.2003.35.3.213
-
Abstract
PDF
- PURPOSE
Gemcitabine and 5-fluorouracil (5-FU) are two compounds with reproducible activity against advanced pancreatic carcinomas. To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty patients (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic pancreatic carcinomas, were enrolled between April 2000 and March 2002. Gemcitabine was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and 5-FU 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the pain, Karnofsky performance status and body weight change measurement.
RESULTS
Nineteen of the twenty patients were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five patients achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 patients. The overall CBR was 41.7% (5/12). The median survival of all the patients was 8.0 months. Grade 3~4 toxicities included neutropenia (9.3%) and thrombocytopenia (5.3%). CONCLUSION: This study suggested that gemcitabine, combined with infusional 5-FU, was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced pancreatic cancer patients.
- 3,830 View
- 32 Download
- The Prognostic Significance of the Overexpression of HER-2/ neu in Korean Gastric Carcinomas and the In Vitro Effects of Anti-HER-2/neu Antibody on Cell Growth in the Gastric Carcinoma Cell Lines
- Seock Ah Im, Kyung Eun Lee, Eunmi Nam, Seung Hyun Nam, Do Yeun Kim, Chu Myong Seong, Hae Young Park, Woon Sup Han, Ju Young Seoh, Soon Nam Lee
- Cancer Res Treat. 2003;35(2):109-116. Published online April 30, 2003
- DOI: https://doi.org/10.4143/crt.2003.35.2.109
-
Abstract
PDF
- PURPOSE
The HER2 gene encodes a 185-kd transmembrane glycoprotein receptor (p185(HER2)) that has partial homology with the epidermal growth factor receptor (EGFR) and shares intrinsic tyrosine kinase activity. The HER2 gene has been found to be amplified in various human cancers and to be associated with poor prognosis. The authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor. MATERIALS AND METHODS: We evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years). Protein expression was analysed by immunohistochemical staining in paraffin embedded tissues with monoclonal antibody for p185(HER2). To explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed. RESULTS: p185(HER2) overexpression correlates positively with lymph node metastasis (p=0.002), distant metastasis (p=0.01), AJCC classification (p=0.01), higher relapse rate p=0.001), and a tendential association with the pT stage (p=0.054). p185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008). Patients with overexpression of p185(HER2) were found to have significantly lower relapse-free (p=0.003) and overall survival (p= 0.0004) than patients without overexpression. Among several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2). Trastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression. DNA fluorescence flow cytometry of propidium iodide-stained nuclei showed a reduction in the fraction of the S phase following treatment with trastuzumab. CONCLUSIONS: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism. This suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer. -
Citations
Citations to this article as recorded by- A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
A. V. Avgustinovich, S. G. Afanasyev, L. V. Spirina, E. V. Kaygorodova, R. V. Ermolenko, E. N. Samtsov, I. G. Frolova, O. V. Cheremisina
Siberian journal of oncology.2024; 23(1): 170. CrossRef - The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
Feng‐Hua Wang, Lin Shen, Jin Li, Zhi‐Wei Zhou, Han Liang, Xiao‐Tian Zhang, Lei Tang, Yan Xin, Jing Jin, Yu‐Jing Zhang, Xiang‐Lin Yuan, Tian‐Shu Liu, Guo‐Xin Li, Qi Wu, Hui‐Mian Xu, Jia‐Fu Ji, Yuan‐Fang Li, Xin Wang, Shan Yu, Hao Liu, Wen‐Long Guan, Rui‐Hu
Cancer Communications.2019; 39(1): 1. CrossRef - The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer
Hyunho Kim, Sang Mi Ro, Ji Hyun Yang, Joon Won Jeong, Ji Eun Lee, Sang Young Roh, In-Ho Kim
The Korean Journal of Internal Medicine.2018; 33(5): 990. CrossRef - Potential Prognostic Significance of p185HER2 Overexpression with Loss of PTEN Expression in Gastric Carcinomas
Seock-Ah lm, Kyung Eun Lee, Eunmi Nam, Do Yeun Kim, Joo-Ho Lee, Ho-Seong Han, Ju-Young Seoh, Hae-Young Park, Min-Sun Cho, Woon Sup Han, Soon Nam Lee
Tumori Journal.2005; 91(6): 513. CrossRef
- A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
- 4,634 View
- 53 Download
- 4 Crossref
Case Report
- A Case of Primary Gastric Choriocarcinoma Presenting with Amenorrhea
- Seung Hyun Nam, Seock Ah Im, Ki Sun Bae, In Sook Kang, Jung Mi Kwon, Kyung Eun Lee, Hye Sung Moon, Sun Hee Sung, Woon Sup Han, Chu Myong Seong, Soon Nam Lee
- Cancer Res Treat. 2002;34(6):457-460. Published online December 31, 2002
- DOI: https://doi.org/10.4143/crt.2002.34.6.457
-
Abstract
PDF
- Primary gastric choriocarcinomas are very rare, and their prognosis is extremely poor. A 37-year-old woman presented with amenorrhea, vaginal spotting and severe nausea, which mimicked a pregnancy and gestational trophoblastic disease. The serum level of the beta-subunit of human chorionic gonadotrophin (beta-hCG) was significantly increased. An endoscopic biopsy of the stomach mass showed the features of a choriocarcinoma, with marked anaplasia and necrosis. Immunohistochemical staining for beta-hCG showed positive results in the choriocarcinoma. Chemotherapy for the choriocarcinoma was administered, but she died 8 months following diagnosis.
-
Citations
Citations to this article as recorded by- Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures
Jung Ho Yoon, Min Soo Kim, Eun Hee Kook, Se Han Ahn, Se Young Jeong, Min Sung Han, Jung Kwon Huh, Hye Jin Kang, Im Il Na, Soo Youn Cho, Sang Bum Kim, Baek Yeol Ryoo, Sung Hyun Yang
Cancer Research and Treatment.2008; 40(3): 145. CrossRef
- Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures
- 4,335 View
- 34 Download
- 1 Crossref
Original Articles
- Clinical Features and Prognosis of Lung Cancer with Brain Metastasis
- Kyung Eun Lee, Eun Mi Nam, He Jin Lee, Seung Hyun Nam, Do Yeun Kim, Seock Ah Im, Chu Myung Seong, Soon Nam Lee, Kyung Ja Lee
- Cancer Res Treat. 2001;33(3):250-255. Published online June 30, 2001
- DOI: https://doi.org/10.4143/crt.2001.33.3.250
-
Abstract
PDF
- PURPOSE
Brain metastasis is estimated to occur in 20~40% of solid tumor patients and the most common primary tumor is lung cancer. Even though the prognosis of brain metastasis is grave and the 1-year survival rate is only 15%, symptom palliations are made with whole brain radiation therapy. We retrospectively evaluated the clinical features and prognostic factors of lung cancer with brain metastasis.
MATERIALS AND METHODS
From January 1987 to October 1999, 50 lung cancer patients with brain metastasis underwent whole brain radiation therapy. We reviewed the improvement in neurologic symptoms and survival according to the following parameters; performance status, histological type, presence of brain metastasis at the initial diagnosis of lung cancer, presence of extracranial metastasis, multiplicity of brain lesion, presence of primary lung symptom and treatment modalities.
RESULTS
The most frequent symptom with brain metastasis was a headache (50%). Palliation of the headache and other symptoms was achieved in 81% of the patients. Median overall survival after brain metastasis was 21 weeks and the 1 year survival rate was 15%. Patients without extracranial metastasis had a longer median survival than those with, 38 weeks versus 15 weeks, respectively (p=0.01).
CONCLUSION
In lung cancer with brain metastasis, neurologic symptoms can be palliated with whole brain radiation therapy, and in this study among such patients, absence of extracranial metastasis can be a good prognostic factor. -
Citations
Citations to this article as recorded by- Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
Cancers.2023; 15(11): 3015. CrossRef
- Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
- 4,732 View
- 48 Download
- 1 Crossref
- Antiangiogenesis Gene Therapy Using Adenovirus-mediated Antisense-VEGF in Glioblastoma Multiforme
- Seock Ah Im, Jeong Soo Kim, Eunmi Nam, Soon Nam Lee
- J Korean Cancer Assoc. 2000;32(4):764-774.
-
Abstract
PDF
- PURPOSE
Vascular endothelial growth factor (VEGF) is a major positive effector of angiogenesis. We investigated the mechanism of tumor growth inhibition by adenoviral transfer of antisense- VEGF in glioma and the role of VEGF for in vivo growth of human glioma cells according to the stage of the tumor growth.
MATERIALS AND METHODS
Replication-deficient adenoviral vector containing the VEGF cDNA in an antisense orientation (Ad5CMV-alphaVEGF) were constructed to increase the in vivo applicability of antisense sequence. The effect of Ad5CMV-alphaVEGF was studied in vitro and in vivo with human glioma cell line U-87 MG. Immunohistochemical staining of the subcutaneous tumor with anti-VEGF antibody and CD34 antibody were performed to compare VEGF protein expression and the microvessel count respectively.
RESULTS
The growth curve of U-87 MG cells treated with Ad5CMV-alphaVEGF remained as same as that of mock-infected and Ad5(dl312)-infected U-87 MG cells in vitro, suggesting that Ad5CMV-alphaVEGF does not have direct cytotoxic effect. The growth of subcutaneous human glioma xenografts was inhibited by early intratumoral injection of Ad5CMV-alphaVEGF. Immuno histochemical staining of tumors showed that VEGF protein expression and mean microvessel counts were decreased in early Ad5CMV-alphaVEGF treatment group.
CONCLUSION
The efficient down-regulation of VEGF produced by tumor cells using Ad5CMV- alphaVEGF in early stage of glioma growth has an antitumor effect in vivo through antiangiogenic mechanism.
- 2,410 View
- 15 Download
- The Prognostic Role of Vascular Endothelial Growth Factor (VEGF) Expression and Angiogenesis in Curatively Resected Non-Small Cell Lung Cancer
- Soon Nam Lee
- J Korean Cancer Assoc. 1999;31(6):1210-1218.
-
Abstract
PDF
- PURPOSE
Angiogenesis is an essential component of tumor growth and metastasis, and vascular endothelial growth factor (VEGF) is one of the important angiogenic factor. To evaluate the prognostic roles of angiogenesis and VEGF expression in patients with non-small cell lung cancer, the relationships between microvessel counts (MVC), VEGF expressions in tumor tissues, clinicopathologic features and overall survival were analysed.
MATERIALS AND METHODS
Thirty-seven patients with curatively resected non-small cell lung cancer were evaluated. Tumor tissues were stained by anti-CD34 and anti-VEGF monoclonal antibody using immunohistochemical method to assess MVC and VEGF expression and analysed the relationship of MVC, VEGF, and clinicopathologic findings.
RESULTS
Mean MVC of all tumor tissues was 33.89+/-24.12 and VEGF were expressed in 26 tissues (70%). There was no correlation between VEGF expression and MVC. Mean MVC was significantly higher in patients with recurrence than in those without recurrence (50.58+/-29.33 vs 19.5+/-11.7, p=0.004). There were no correlation between VEGF expression and clinicopathologic findings and overall survival. In univariate analysis, MVC (p=0.0431), lymph node involvement (p=0.0046), histologic type (squamous vs nonsquamous) (p=0.0072) were significant prognostic factors with respect to overall survival.
CONCLUSION
In patients with non-small cell lung cancer who underwent curative resectin of tumors, VEGF expression in tumor tissue was not correlated with MVC and survival. But MVC was correlated with tumor recurrence and survival, thus MVC may be used as one of prognostic factors in non-small cell lung cancer.
- 2,718 View
- 19 Download
- A Phase 2 Study with Vinorelbine and Ifosfamide in the Inoperable Non - small Cell Lung Cancer
- Moon Hee Lee, Young Jin Yoo, Soo Mi Bang, Gyung Hae Joung, Hyo Jin Kim, Dong Bok Shin, Soon Nam Lee, Seong Rok Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
- J Korean Cancer Assoc. 1999;31(5):972-978.
-
Abstract
PDF
- PURPOSE
A phase II study of vinorelbine and ifosfamide combination chemotherapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC) was conducted to assess response rate, response duration, and toxicites.
MATERIALS AND METHODS
Patients with advanced NSCLC who had no prior systemic chemotherapy were eligible. They have no central nervous system metastasis and recurrent or progressive disease after surgery or radiotherapy. Each cycle consisted of vinorelbine 25 mg/m' i.v. days 1 & 8, and ifosfamide 2 g/m i.v. days 1, 2 & 3 with Mesna and treatments were repeated every 21 days.
RESULTS
Forty patients with advanced or recurrent NSCLC were treated at multi center between March, 1997 and March, 1998. Six patients were not evaluable because five patients refused therapy after the first course and one patient was protocol violation. Of 34 evaluable patients, objective responses were seen in 11 (32.4%) patients (CR 0%, PR 32.4%). The median duration of response was 16.4 weeks. The median overall survival was 9.5 months. The toicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION
We concluded that combination regimen of vinorelbine and ifosfamide was effective and tolerable in the treatment of advanced non-small cell lung cancer.
- 2,515 View
- 16 Download
- Germline Mutation of BRCA2 Gene in Korean Breast / Ovarian Cancer Families
- Yong Jin Won, Jae Hwan Oh, Ji Hyun Kim, Dong Young Noh, Kuk Jin Choe, Soon Beom Kang, Lee Su Kim, Man Su Ro, Nam Sun Paik, Dae Hyun Yang, Se Min Oh, Soon Nam Lee, Kyung Kook Kim, Jae Gahb Park
- J Korean Cancer Assoc. 1998;30(2):242-252.
-
Abstract
PDF
- PURPOSE
Recent discovery of BRCA1 and BRCA2 genes has made it possible to perform presymptomatic diagnosis in hereditary breast/ovarian cancer families. We have previously reported germline mutations of the BRCA1 gene in Korean hereditary breast/ovarian cancer families. In that study two out of 13 families were found to have germline mutations in BRCA1 gene. One was a nonsense mutation in codon 1815, and the other was a frameshift mutation due to 2 base-pair deletion in codon 1701 of BRCA1 gene. This study was intended to identify germline mutations of the BRCA2 gene in Korean breast/ovarian cancer families.
MATERIALS AND METHODS
Peripheral blood DNA was obtained from 10 breast cancer patients registered at the Korean Hereditary Tumor Registry with positive family history of breast and/or ovarian cancer. Exons 11 and 27 of the BRCA2 gene(together accounting for 50% of the coding region of the BRCA2 gene) were amplified by polymerase chain reaction(PCR) and screened for mutations by in vitro transcription/translation method. For confirmation of the mutations, automatic sequencing of the PCR products displaying abnormal truncated protein bands was perfomed.
RESULT
We identified an abnormal truncated protein in the exon 11 of the BRCA2 gene from a member of hereditary breast cancer family, SNU-B4. Sequencing analysis revealed a 4 bp deletion in codons 1248-49 of the exon 11, resulting in frameshift that led to premature stop codon and truncation of the protein product.
CONCLUSION
We have identified a germline mutation from a Korean hereditary breast cancer family. So far only one case of the same mutation has been registered in Database of BRCA2 mutation (BIC) by a commercial genetic diagnosis company, Myriad Genetics, Inc. Identification of the germline mutation in BRCA2 gene should aid in the accurate presymptomatic diagnosis of the at-risk members in this family.
- 3,640 View
- 34 Download
- Germline Mutations of BRCA1 Gene in Korean Breast and/or Ovarian Cancer Families
- Yong Jin Won, Jae Hwan Oh, Xiao Hong Huang, Dong Young Noh, Kuk Jin Choe, Soon Beom Kang, Lee Su Kim, Man Su Noh, Nam Sun Paik, Dae Hyun Yang, Se Min Oh, Soon Nam Lee, Jae Gahb Park
- J Korean Cancer Assoc. 1997;29(5):713-723.
-
Abstract
PDF
- PURPOSE
To understand the involvement of BRCA1 gene in Korean breast and/or ovarian cancer families.
MATERIALS AND METHODS
Germline mutations of BRCA1 gene were analyzed in 13 families which included 3 hereditary site-specific breast cancer families, 6 suspected breast cancer families, and 3 suspected breast-ovarian cancer family, and one Li-Fraumeni family by screening BRCA1 gene using single strand conformation polymorphism (SSCP) analysis on polymerase chain reaction (PCR) amplified genomic DNA and confirmed the results by sequencing.
RESULTS
Including one family with previously reported nonsense mutation of BRCA1 gene, we detected two mutations in unrelated families. One newly identified mutation was frame shift mutation resulting from TG deletion in codon 1701, which results in a truncated BRCA1 protein, at codon 1714.
CONCLUSION
The proportion of families who inherit the mutated BRCA1 gene seems to be small among Korean breast and/or ovarian cancer families.
- 3,284 View
- 27 Download
- Tumor Angiogenesis As a Predictor of Prognosis in Gastric Carcinoma
- Seock Ah Im, Soon Nam Lee, Sung Sook Kim
- J Korean Cancer Assoc. 1997;29(4):640-647.
-
Abstract
PDF
- PURPOSE
Angiogenesis is an essential component of tumor growth and proven to be a prognostic factor in breast, cervix, prostate carcinoma and melanoma. This study was designed to define the relationship of microvessel density with overall survival, clinicopathologic data and with other reported prognostic factors in gastric carcinoma.
METHODS
We studied resected tumor specimens from thirty-two patients with gastric carcinoma who underwent gastrectomy at Ewha Women's University Hospital from January, 1989 to December, 1991. Specimens were investigated by staining with a monoclonal antibody aganist factor VIII-related antigen, which was localized to vascular endothelium. Correlation between the microvessel count (X200), various clinicopathologic factors, EGFR and p53 were studied.
RESULTS
The microvessel count was increased with higher histologic staging. The microvessel count was significantly higher in group with lymph node metastasis than in those without lymph node metastasis (60.7 vs 27.4, p=0.02). In patients with high microvessel count (> or =30), overall survival time was shorter than in those with low count (<30), but insignificant statistically (p>0.05). The microvessel count was higher in group with recurrence than in those without recurrence (48.1 vs 33.2, p=0.05).
CONCLUSION
Microvessel count may be a prognostic indicator in gastric carcinoma but larger scale study should be followed.
- 2,604 View
- 13 Download
- VACOP-B (Etoposide/Doxorubicin/Cyclophosphamide/Vincristine/Prednisolone/Bleomycin) Combination Chemotherapy for the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma
- Young Im Kwak, Young Kug Cheon, Young Hyuck Im, Yoon Koo Kang, Soon Nam Lee, Jhin Oh Lee, Tae Woong Kang
- J Korean Cancer Assoc. 1997;29(1):146-159.
-
Abstract
PDF
- PURPOSE
To determine the antitumor activity of VACOP-B regimen for advanced non- Hodgkin's lymphoma (NHL) in terms of complete response rate, disease free survival, and overall survival, to assess the toxicities of this regimen, and to analyze the prognostic factors influencing the treatment results.Patients and methods: Between Apr. 1991 and Aug. 1993, thirty-six previously untreated patients with the intermediate or high grade NHL were treated with VACOP-B (etoposide/doxorubicin/cyclophosphamide/vincristine/prednisolone/bleomycin) combination chemotherapy. In case of initial bulky disease or residual disease after chemotherapy, radiation therapy of involved field was added.
RESULTS
Complete response (CR) was achieved in 69% (25/36) of the eligible patients after VACOP-B chemotherapy, and 5 of 11 patients who remained in partial response (PR) after chemotherapy achieved CR after additional radiation therapy of involved field, resulting in 83% (30/36) of CR rate. With a median follow-up of 47.2 months, the disease free survival was 1~42.1+ months, and its median was 24 months. The range of survival time was 7~49.1+ months, and the median survival time was not reached at this time. The projected 3-year survival rate was 70%. Leukopenia was observed in 43% of chemotherapy cycles and thrombocytopenia in 2.3%. However, no treatment-related death was observed. For non-hematologic toxicities, nausea and vomiting were observed in 58% of patients, stomatitis in 58%, peripheral neuropathy in 58%, pulmonary toxicity in 3% and congestive heart failure in 3%. These toxicities were tolerable and all reversible. The prognostic factors influencing the complete response rate were performance status of patient (p=0.026) and relative dose intensity of cyclophosphamide (p=0.013).
CONCLUSION
VACOP-B regimen is an effective and tolerable regimen for the intermediate and high grade NHL. And long term follow-up and phase III study will be needed for evaluation of these results compared to previous other treatment modality.
- 4,791 View
- 98 Download
- Inhibition of anticancer chemotherapy-induced stomatitis by oral cryotherapy
- Jung Ran Byun, Ji Sun Kim, Soon Nam Lee
- J Korean Cancer Assoc. 1993;25(5):760-766.
- 2,519 View
- 18 Download
- Alternating Chemotherapy with VIP ( VP-16-213 , Ifosfamide , Cis-Platinum ) and CSV ( Cyclophosphamide , Adriamycin , Vincristi
- Soon Nam Lee, Dae Seog Heo, Noe Kyeong Kim, Young Soo Shim, Keun Youl Kim, Keun Youl Kim, Charn Il Park
- J Korean Cancer Assoc. 1987;19(2):79-87.
-
Abstract
PDF
- Non-cross resistant regimen consisting of VIP rapidly alternating with CAV has been studied in 45 patients with small cell lung cancer. VP-16 60 mg/m i.v. on days 1-5, ifosfamide 1000 mg/m i.v. on days 1-5, and cis-platinum 60 mg/m i.v. on day 1 was alternated at interval of 3 weeks with cyclophosphamide 1000 mg/m i.v. on day 1, adriamycin 45 mg/m i.v. on day 1 and vincristine 1. 4 mg/m i.v. on day 1. For 27 patients with limited disease, indution chemotherapy with one cycle of VIP and CAV was followed by radiotherapy to primary tumor, both supraclavicular lymph nodes and prophylactic whole brain irradiation. Three to four weeks after the completion of radiotherapy, 12 cycles of VIP and CAV were maintained. Eighteen patients with extensive disease were treated with chemotherapy alone. The results obtained were as follows; I) A 92.6% overall response rate and 44.S% complete remission rate in limited disease and 61. 1% overall response rate and 11.1% complete remission rate in extensive disease were achieved. Overall resonse rate in both stage disease was 80.0% and the rate of complete and partial remission was 33.3% and 46.6% respectively. 2) The overall median duration of remission was 49.2 weeks. The median duration of remission was not reached in limited disease group (range, 4-92+weeks) and 34.5 weeks in extensive disease group. The duration of remission for the complete responders was much longer than that for the partial responders (P<0.01).
- 2,442 View
- 14 Download
- Anti - Emetic Effect of Ondansetron Combined with Dexamethasone in Cisplatin Induced Nausea and Vomiting
- Wook Bum Pyun, Seong Nam Kim, Sung Ae Jung, Soon Nam Lee
- J Korean Cancer Assoc. 1994;26(1):151-158.
-
Abstract
PDF
- Cisplatin, an agent highly effective against a variety of cancers, produces the most severe nausea and vomiting of any chemotherapeutic agents. Recently, the role of 5-HT,(serotonin) in cisplatin induced nausea and vomiting was introduced and ondansetron a selective 5-HT, receptor antagonist, was administered to prevent cisplatin induced nausea and vomiting. Remarkable effects on acute emesis was obtained but effects on delayed emesis was not controlled by ondansetron only. This study was done to investigate the effectiveness and side effects of ondsnsetron combined with dexamethasone in cisplatin induced nausea and vomitiog. To evaluate the effetiveness of ondansetron combined with dexamethasone in preventing cisplatin induced nause and vomiting, 16 cancer patients who were treated with intravenous cisplatin containing chemotherapy as the first anticancer therapy were administered 20 mg dexamethasone i.v. 20 minutes before and 8 mg ondansetron i.v. 15 minutes before, 4 hour and 8 hour after ciaplatin infusion respectively on day 1, and 8 mg ondansetron was administered orally three times a day on day 2-4. On the first day, the complete response and major response were noted in 75%(12/16 patients), and 19%(3/l6 patients) respectively, minor response in 6%(l/16 patients), and none showed failure. On the second day, the complete response and major response were noted in 44 %(7/16 patients) and 25%(4/16 Patients) respectively, minor response in 19%(3/16 patients), and 12%(2/16 patients) showed failure. On the third to fourth day, complete response was noted in 29%(4/14 patients), major response 29%(4/14 patients), and minor response and failure were noted in 21%(3/l4 patientsl respectively. Two patients complained headache, dizziness respectively and the other two patients complained abdominal pain and diarrhea, but the degree was mild and subsided by conservative management. With these results, the administration of ondansetron and dexamethasone to prevent the cisplatin induced nausea and vomiting was effective for acute emesis but not so effective in delayed emesis even with combination of dexamethasone. Further study would be necessary to overcome the low effectiveness on the control of delayed emesis.
- 2,594 View
- 17 Download
- Histologically Transformed Non - Hodgkin's Lymphoma in Pregnancy
- Seock Ah Im, Ki Nam Shim, Soon Nam Lee, Soo Yeon Cho, Hae Soo Koo, Kyung Ja Lee
- J Korean Cancer Assoc. 1994;26(6):1020-1028.
- 2,628 View
- 12 Download
- The Effect of Perioperative Blood Transfusion on the Prognosis of Colorectal Cancer Patients
- Hee Jung Choi, Jin Hyuk Choi, Soon Nam Lee, Eung Bum Park, Kyung Ja Lee
- J Korean Cancer Assoc. 1995;27(3):403-411.
-
Abstract
PDF
- Except for the weli known prognostic factors of cancer, the studies that perioperative transfusion of surgically resectable cancer could influence the survival of cancer patients were continued to be investigated. The explanation of deleterious effects of transfusion has been supported by the results that the incidences of renal allograft rejection were decreased by pretransplantation tranafusion, and transfusion resulted in changes of mononuclear cell function and inhibited natural killer cell activity. But definite proof of this adverse eifect has not been settled. We investigated whether perioperative transfusion can diminish the eurvival rate of patients with colorectal cancer and transfusion itself can become prognostic factor by way of retrospec- tive analysis of 104 surgically resected colorectal cancer patients. Five year survival rate of 46.2% in transfusion group(n=53) is significantly decreased compared with the rate of 73.8% in non-transfusion group(n=51) (P<0.05). In subgroup analysis, there is no difference in survival rate by stage, the amount and component of blood transfusion. There are many other variables that can affect survival rate of cancer patient except for transfusion, multivariate Cox regression analysis was performed. The tumor differentiation is the greatest relative risk, but transfusion itself is not an independent prognostic value. In conclusion, perioperative transfusion and the swvival rate did not show direct relationship in these surgically resected coiorectal cancer patients. Nevertheless the difference in survival rate between transfusion group and non-transfusion group is significant, judicious use of blood products, use of frozen washed red blood cells that are totally lacking in white cells might be necessary. To confirm the direct causal relationship between perioperative transfusion and the survival in colorectal cancer, the larger prospective investigations are thought to be needed.
- 3,219 View
- 17 Download
- A Case of Concurrent Occurrence of Small Cell Carcinoma and Adenocarcinoma in the Stomach
- Ki Nam Shim, Sa Young Park, Sun Young Lee, Jin Hyuk Choi, Soon Nam Lee, Woon Sup Han
- J Korean Cancer Assoc. 1995;27(3):513-521.
-
Abstract
PDF
- Frimary small cell careinoma of the stomach is an extremely rare disease. It has similar clinical behavior with small cell cardnoma of lung, which shows aggressive course with rapid and wide dissemination and very poor prognosis. We report a case of concurrent occurrence of primary small cell carcinoma and adeno- carcinoma in the stomach with multiple intraaMominal metastases, which had responded to combination chemotherapy with 5-FU, VP-16, and Cisplatin.
- 2,402 View
- 13 Download
- Antiemetic Effect of Granisetron in Cisplatin - Induced Nausea and Vomiting
- Seock Ah Im, Hee Jung Choi, Ki Youl Seo, Ki Youl Seo, Jin Hyuk Choi, Soon Nam Lee
- J Korean Cancer Assoc. 1995;27(6):1040-1048.
-
Abstract
PDF
- Cisplatin is an highly effective agent against a variety of cancers but produces the most severe nausea and vomiting compared with other chemotherapeutic agents. Recently the role of 5-HT,(serotonin) in cisplatin induced nausea and vomiting was introduced and serotonin receptor antagonists seem to be as effective as corticosteroids in preventing cisplatin-induced emesis. From October 1994 to August 1995, we evaluate antiemetic effect of granisetron, a selective 5-HT, receptor antagonist, in 20 patients (M:F=11:9) who receiving their first course of combination chemotherapy containing high dose cisplatin(100 mg/§³). Granisetron 3 mg was given intravenous infusion before 100 mg/§³ of cisplatin infusion. In first 24 hours after chemotherapy, complete response achieved in 18 of 20 patients(90%). First episode of vomiting developed at 31.5¡¾20.3 hours after cisplatin infusion. For delayed emesis, on second day, complete response achieved in ll of 18 patients (61%), major response in 4 of 18 patients (22%), minor response in 3 patients (17%) and from third to seventh day, complete response achieved in 8 of 18 patients (44%), major response in 7 of 18 patients (39%), minor response in 3 patients (17%). Most commonly reported adverse effect of granisetron was headache. In conclusion, granisetron was an effective antiemetic agent in preventing cisplatin induced acute emesis but not so effective in delayed emesis. For better control of delayed emesis, new combination antiemetic therapy should be investigated.
- 2,859 View
- 14 Download
- Germline Mutation of BRCA1 Gene in Korean Breast and Overian Cancer Patients
- Jae Hwan Oh, Dong Young Noh, Kuk Jin Choe, Soon Beom Kang, Lee Su Kim, Man Su Ro, Nam Sun Paik, Dae Hyun Yang, Se Min Oh, Soon Nam Lee, Jae Gahb Park
- J Korean Cancer Assoc. 1995;27(6):1061-1070.
-
Abstract
PDF
- We analyzed germline mutations of the BRCAl gene in 29 Korean breast cancer patients, which included ¨c 10 breast cancer patients with family history of breast or ovarian cancer, ¨e 7 early onset breast cancer patients without family history of breast or ovarian cancer(1ess than 40 years old at diagnosis) and ¨e 12 breast cancer patients without family history of breast or ovarian cancer(more than 40 years old at diagnosis), and 1 hereditary ovarian cancer patient. One nonsense mutation at codon 1815 encoding a truncated protein was detected in a breast cancer patient with family history of ovarian cancer. One missense mutation at codon 1630 was detected in a group of breast cancer patients without family history(more than 40 years old at diagnosis), but still not determined whether it was polymorphism or not. Three polymorphisms were detected, which included 2 cases of silent mutation and a case of missense mutation. In early onset breast cancer group and a familial ovarian cancer patient, there was no detected mutation. We confirmed a germline BRCAl gene mutation in one Korean patient of hereditary breast-ovarian cancer family.
- 3,632 View
- 34 Download
- Carcinosarcoma of the Esophagus
- Seock Ah Im, Ki Youl Seo, Hye Young Son, Mi Sung Shin, Doe Young Kim, Soon Nam Lee, Soo Seung Choi, Mi Jung Kim, Sung Sook Kim, Young Guk Lim
- J Korean Cancer Assoc. 1996;28(1):168-175.
-
Abstract
PDF
- Carcinosarcoma of the esophagus is a rare neoplasm composed of both carcinomatous and sarcomatous area. Usually the carcinomatous component is a squamous cell carcinoma. The histogenesis of the sarcomatous component is still unknown but consider as transformation from carcinomatous portion. We report a case of carcinosarcoma of esophagus in a 65 year-old male patient who was taken radical esophagectomy with lymph node dissection, Microscopically it was composed of squamous cell carcinoma intermingled with sarcomatous component in polypoid portion.
- 2,889 View
- 16 Download
- Determination of Serum CEA Level in Primary Lung Cancer
- Jin Hyuk Choi, Jung Hyun Chang, Soon Nam Lee, Eun Mi Nam, Ki Ryung Park, Sa Young Park, Hyo Jin Lee, Sung Min Cho, Young Sun Kim, Ka Eun Woo, Na Young Lee, Na Young Lee, Kwang Ho Kim
- J Korean Cancer Assoc. 1996;28(2):281-286.
-
Abstract
PDF
- Background
The role of serum carcinoembryonic antigen(CEA) as a tumor marker in primary lung cancer remains unanswered. Several reports suggested that usefulness of serum CEA was limited to specific histologic types or clinical situations. Methods: Serum levels of CEA were determined in 126 patients with primary lung cancer and its correlation with clinico-pathologic characteristics was investigated. Results: Serum CEA was positive (defined as>5ng/ml) in 71 patients(56.3%). The positivity of serum CEA was significantly higher in adenocarcinoma(72.3%) than that in squamous cell carcinoma(46.5%) and small cell carcinoma(44.0%) (p=0.025). There was no significant difference in positivity of CEA according to sex and stages. Conelueion: Serum CEA does not seem to be standard tumor marker of primary lung cancer. However, it could be useful as prognostic factor or monitor of treatment results, especially in adenocarcinoma.
- 3,509 View
- 16 Download
First
Prev
